Trial Profile

A Phase II, Open-label, Multicenter Study of Abemaciclib and Letrozole in Patients with Estrogen Receptor-positive Rare Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Letrozole (Primary)
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms ALEPRO

Most Recent Events

19 Mar 2025 Planned End Date changed from 1 Oct 2026 to 1 Jan 2028.
19 Mar 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Jan 2028.
01 Apr 2024 Patient recruitment will be completed by the end of 2025 and reporting of the final study results will be done by the end of 2027, as per design published in the International Journal of Gynecological Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com